Anadys Pharmaceuticals Announces Successful Outcome Of ANA598 Healthy Volunteer Study And Finalization Of Study Design For Phase Ib Trial In HCV
Sep 30th 2008Drug InformationLiver Disease / Hepatitis
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced preliminary results of a Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). In the healthy volunteer study, ANA598 was well tolerated at all doses analyzed to date and no serious adverse events were reported.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
